This article was originally published in The Tan Sheet
The rates of treatment and control of high cholesterol are "far from optimal," especially among individuals at intermediate and high risk for cardiovascular disease, a study published in the Feb. 7 Circulation finds. Roughly half of the individuals at high- and intermediate-risk of CVD had untreated high cholesterol, or dyslipidemia, compared to less than 20% of individuals in the low-risk group. Additionally, "there is evidence of gender and ethnic disparities in both treatment and control," David Goff, MD/PhD, Wake Forest University School of Medicine, et al., state. "Efforts to improve the treatment and control of dyslipidemia and to eliminate disparities...should be considered among our highest national healthcare quality improvement priorities," they conclude. Goff et al. evaluated 6,704 patients from the Multi-Ethnic Study of Atherosclerosis, a cohort study of individuals between 45-84 years old who were free of clinical CVD at baseline (2000-2002)...
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.